<DOC>
	<DOCNO>NCT00941083</DOCNO>
	<brief_summary>A switch protease inhibitor ( PIs ) raltegravir ( RAL ) effective virologically immunologically . Moreover , associate significant improvement lipid profile HIV patient undetectable viremia PIs . In set , RAL day ( QD ) perform well RAL twice day ( BID ) .</brief_summary>
	<brief_title>Simplification From Protease Inhibitors Raltegravir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 seropositive use standard diagnostic criterion Plasma viral HIVRNA 50 copies/ml within 180 day prior randomization On therapy protease inhibitor ritonavirboosted unboosted least 6 month prior study entry Pregnancy breast feed Prior use Integrase inhibitor Alcohol substance abuse accord investigator opinion would interfere compliance UIse investigational medication within 30 day study entry trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Simplification protease inhibitor raltegravir</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV-1 Infections</keyword>
</DOC>